PEGylated polycyanoacrylate nanoparticles as vector for drug delivery in prion diseases.
PEGylated polymeric nanoparticles are hereby presented as a potential efficient drug carrier for the delivery of active therapeutic molecules in prion experimental diseases. Based on their blood long-circulating characteristics, these PEGylated particles made by the amphiphilic copolymer poly [methoxy poly(ethylene glycol) cyanoacrylate-co-hexadecyl cyanoacrylate] (PEG-PHDCA), showed comparatively conventional non-PEGylated nanoparticles, a higher uptake by the spleen and the brain which are both the target tissues of PrPres accumulation in scrapie infected animals.
Calvo
P
P
UMR CNRS 8612, Physico-Chimie-Pharmacotechnie-Biopharmacie, Faculté de Pharmacie, Université Paris-Sud XI, 5, rue Jean Baptiste Clément, 92296, Châtenay-Malabry, France.
Gouritin
B
B
Brigger
I
I
Lasmezas
C
C
Deslys
J
J
Williams
A
A
Andreux
J P
JP
Dormont
D
D
Couvreur
P
P
D000818:Animals; D001672:Biocompatible Materials / Q000493:pharmacokinetics; D001769:Blood / Q000378:metabolism; D001921:Brain / Q000378:metabolism; D003487:Cyanoacrylates / Q000493:pharmacokinetics; D004337:Drug Carriers; D007275:Injections, Intravenous; D008297:Male; D009994:Osmolar Concentration; D010316:Particle Size; D011092:Polyethylene Glycols / Q000493:pharmacokinetics; D051381:Rats; D012608:Scrapie / Q000188:drug therapy* / Q000503:physiopathology; D014018:Tissue Distribution
D001672:Biocompatible Materials; D003487:Cyanoacrylates; D004337:Drug Carriers; C121140:polyethyleneglycol polyhexadecylylcyanoacrylate copolymer; D011092:Polyethylene Glycols